EUVIMEDSkopri EUVIMED
Randomisierte kontrollierte Studie

Effect of synbiotics on weight loss and metabolic health in adults with overweight and obesity: A randomized controlled trial

John Lyon, Mary Connell, Kartik Chandrasekaran, Shalini Srivastava iD

Obesity · 2023

DOI: 10.1002/oby.23801 ↗

At a glance

Randomisierte kontrollierte Studie in Obesity, 2023. Written by John Lyon and 3 co-authors. Institution: Product Development Department, Veyl Ventures-DBA Netbus Inc., New York, New York, USA. Major MEDLINE topics: Overweight, Synbiotics. Cited 7 times so far (Crossref); 33 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

Objective

The study aimed to investigate the effect of synbiotics on body composition and metabolic health in individuals with excessive body weight.

Methods

The 12‐week randomized, double‐blind, placebo‐controlled clinical trial had individuals aged 30 to 60 years with BMI of 25 to 34.9 kg/m 2 . In total, 172 participants were randomly allocated to either synbiotic V5 or V7 groups or the placebo group. The primary outcome was change in BMI and body fat percentage. Secondary outcomes were changes in weight, other metabolic health and inflammatory markers, gastrointestinal quality of life, and eating behaviors.

Results

The V5 and V7 groups had a significant reduction in BMI ( p < 0.0001) from baseline to the end of the study, as opposed to the nonsignificant change in the placebo group ( p = 0.0711). This reduction in the V5 and V7 groups was statistically significant when compared individually with the change in the placebo group ( p < 0.0001). This corresponded well with the decrease in body weight with V5 and V7 ( p < 0.0001). In addition, compared with placebo, the increase in high‐density lipoprotein was statistically significant in the V5 ( p < 0.0001) and V7 groups ( p = 0.0205). A similar trend was observed in the high‐sensitivity C‐reactive protein levels, with a statistically significant decrease in the V5 ( p < 0.0001) and V7 (0.0005) groups.

Conclusions

The study demonstrates that synbiotic V5 and V7 were effective in reducing body weight in individuals with lifestyle modification.

Subjects

MeSH terms (MEDLINE)

OverweightSynbioticsHumansAdultQuality of LifeBiomarkersObesityDouble-Blind MethodWeight Loss

Substances

Biomarkers

Authors and institutions

  • Product Development Department, Veyl Ventures-DBA Netbus Inc., New York, New York, USA.
  • Research Department, Veyl Ventures-DBA Netbus Inc., New York, New York, USA.
  • Supply Chain Department, Veyl Ventures-DBA Netbus Inc., New York, New York, USA.
  • Clinical Development Department, Vedic Lifesciences Pvt. Ltd., Mumbai, Maharashtra, India.

ORCID profiles: Shalini Srivastava

Cite

APA

Lyon, J., Connell, M., Chandrasekaran, K., & Srivastava, S. (2023). Effect of synbiotics on weight loss and metabolic health in adults with overweight and obesity: A randomized controlled trial. Obesity. https://doi.org/10.1002/oby.23801

Vancouver

Lyon J, Connell M, Chandrasekaran K, Srivastava S. Effect of synbiotics on weight loss and metabolic health in adults with overweight and obesity: A randomized controlled trial. Obesity. 2023. doi:10.1002/oby.23801

BibTeX
@article{Lyon2023,
  author = {Lyon, John and Connell, Mary and Chandrasekaran, Kartik and Srivastava, Shalini},
  title = {Effect of synbiotics on weight loss and metabolic health in adults with overweight and obesity: A randomized controlled trial},
  journal = {Obesity},
  year = {2023},
  doi = {10.1002/oby.23801}
}
Start for free →